GCP
PGNX

GSA Capital Partners’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

GSA Capital Partners’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-56,543
Closed -$336K – 1929
2017
Q4 		$336K Buy
+56,543
New +$344K 0.02% 1158
2017
Q3 		– Sell
-144,743
Closed -$983K – 1979
2017
Q2 		$983K Buy
+144,743
New +$1.07M 0.06% 556
2017
Q1 		– Sell
-18,890
Closed -$163K – 2114
2016
Q4 		$163K Buy
+18,890
New +$140K 0.01% 1633
2016
Q3 		– Sell
-13,100
Closed -$55K – 2067
2016
Q2 		$55K Sell
13,100
-375,200
-97% -$1.81M ﹤0.01% 1695
2016
Q1 		$1.69M Sell
388,300
-46,423
-11% -$207K 0.11% 254
2015
Q4 		$2.67M Sell
434,723
-43,101
-9% -$283K 0.13% 162
2015
Q3 		$2.73M Buy
477,824
+164,034
+52% +$1.26M 0.13% 147
2015
Q2 		$2.34M Buy
313,790
+128,199
+69% +$776K 0.09% 275
2015
Q1 		$1.11M Buy
185,591
+144,214
+349% +$908K 0.04% 779
2014
Q4 		$313K Buy
41,377
+20,497
+98% +$123K 0.02% 1237
2014
Q3 		$108K Buy
+20,880
New +$104K 0.01% 1616
2014
Q2 		– Sell
-10,080
Closed -$41K – 2024
2014
Q1 		$41K Buy
+10,080
New +$51.5K ﹤0.01% 1518

Other funds holding PGNX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CTA
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

GSA Capital Partners's PGNX Position: Q1 2018 in Review

GSA Capital Partners sold out of Progenics Pharmaceuticals Inc (PGNX) in Q1 2018, closing a stake of 56,543 shares — an estimated $336K sold.

GSA Capital Partners first reported a position in PGNX in Q1 2014 and held it in 12 quarters. The position peaked at $2.73M in Q3 2015. 152 funds tracked by Wall St. Rank hold PGNX as of Q1 2018.

  • GSA Capital Partners reported no remaining Progenics Pharmaceuticals Inc position as of Q1 2018 after selling out during the quarter.
  • GSA Capital Partners sold 56,543 Progenics Pharmaceuticals Inc shares in Q1 2018, an estimated $336K.
  • GSA Capital Partners first reported a position in Progenics Pharmaceuticals Inc in Q1 2014 and held it in 12 quarters.
  • GSA Capital Partners's Progenics Pharmaceuticals Inc position peaked at $2.73M in Q3 2015.
  • 152 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q1 2018.

Based on GSA Capital Partners's 13F filing for Q1 2018, filed 11 May 2018.